Literature DB >> 2351184

Accurate quantification of 131I distribution by gamma camera imaging.

A J Green1, S E Dewhurst, R H Begent, K D Bagshawe, S J Riggs.   

Abstract

The development of targeted therapy requires that the concentration of the therapeutic agent can be estimated in target and normal tissues. Single photon emission tomography (SPET), with and without scatter correction, and planar imaging using 131I have been compared to develop a method for investigation of targeted therapy. Compton scatter was investigated using line spread functions in air and water, these data were used to set a second peak, adjacent to the photopeak, for scatter correction. The system was calibrated with an eliptical phantom containing sources in background activity of various intensities. Scatter corrected reconstructions gave accurate estimates of activity in the sources regardless of background activity. For planar scanning and SPET without scatter correction there was an overestimate of activity in the source of 290% and 40% respectively. The validity of this method was confirmed in patients by comparing activity in the cardiac ventricles measured by SPET with scatter correction with that in a simultaneous blood sample. A coefficient of correlation of 0.955 was achieved with 25 data points. SPET with scatter correction was compared with planar imaging in measuring activity in the liver and spleen of patients receiving 75 mCi 131I-antibody to CEA intravenously. Planar imaging gave significantly higher values than SPET for the spleen (t = 5.4, P less than 0.001 by the paired t-test) but no significant difference for the liver. SPET with scatter correction forms a basis for an improved technique of quantifying the targeting efficiency.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2351184     DOI: 10.1007/bf00842793

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  9 in total

1.  In vivo quantitation of lesion radioactivity using external counting methods.

Authors:  S R Thomas; H R Maxon; J G Kereiakes
Journal:  Med Phys       Date:  1976 Jul-Aug       Impact factor: 4.071

2.  Improved SPECT quantification using compensation for scattered photons.

Authors:  R J Jaszczak; K L Greer; C E Floyd; C C Harris; R E Coleman
Journal:  J Nucl Med       Date:  1984-08       Impact factor: 10.057

3.  Dosimetry of 131I-labeled anti-ferritin in hepatoma: a model for radioimmunoglobulin dosimetry.

Authors:  P K Leichner; J L Klein; J B Garrison; R E Jenkins; E L Nickoloff; D S Ettinger; S E Order
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-03       Impact factor: 7.038

4.  Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning.

Authors:  D M Goldenberg; F DeLand; E Kim; S Bennett; F J Primus; J R van Nagell; N Estes; P DeSimone; P Rayburn
Journal:  N Engl J Med       Date:  1978-06-22       Impact factor: 91.245

5.  Radioimmunolocalization and selection for surgery in recurrent colorectal cancer.

Authors:  R H Begent; P A Keep; F Searle; A J Green; H D Mitchell; B E Jones; J Dent; J E Pendower; R A Parkins; K W Reynolds
Journal:  Br J Surg       Date:  1986-01       Impact factor: 6.939

6.  Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments.

Authors:  J A Carrasquillo; K A Krohn; P Beaumier; R W McGuffin; J P Brown; K E Hellström; I Hellström; S M Larson
Journal:  Cancer Treat Rep       Date:  1984-01

7.  External imaging techniques for quantitation of distribution of I-131 F(ab')2 fragments of monoclonal antibody in humans.

Authors:  N D Hammond; P J Moldofsky; M R Beardsley; C B Mulhern
Journal:  Med Phys       Date:  1984 Nov-Dec       Impact factor: 4.071

8.  Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation.

Authors:  J P Mach; S Carrel; M Forni; J Ritschard; A Donath; P Alberto
Journal:  N Engl J Med       Date:  1980-07-03       Impact factor: 91.245

9.  Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A.

Authors:  J A Ledermann; R H Begent; K D Bagshawe; S J Riggs; F Searle; M G Glaser; A J Green; R G Dale
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

  9 in total
  15 in total

1.  Characterization of scatter and penetration using Monte Carlo simulation in 131I imaging.

Authors:  Y K Dewaraja; M Ljungberg; K F Koral
Journal:  J Nucl Med       Date:  2000-01       Impact factor: 10.057

Review 2.  A role for gamma scintigraphy in cancer immunology and immunotherapy.

Authors:  A C Perkins; M V Pimm
Journal:  Eur J Nucl Med       Date:  1992

Review 3.  Monoclonal antibody administration. Current clinical pharmacokinetic status and future trends.

Authors:  R H Begent; R B Pedley; J Begent
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

Review 4.  Scatter correction in scintigraphy: the state of the art.

Authors:  I Buvat; H Benali; A Todd-Pokropek; R Di Paola
Journal:  Eur J Nucl Med       Date:  1994-07

5.  Image quantification for radiation dose calculations--limitations and uncertainties.

Authors:  J M Pereira; M G Stabin; F R A Lima; M I C C Guimarães; J W Forrester
Journal:  Health Phys       Date:  2010-11       Impact factor: 1.316

6.  Accuracy of 131I tumor quantification in radioimmunotherapy using SPECT imaging with an ultra-high-energy collimator: Monte Carlo study.

Authors:  Y K Dewaraja; M Ljungberg; K F Koral
Journal:  J Nucl Med       Date:  2000-10       Impact factor: 10.057

Review 7.  Imaging in targeted delivery of therapy to cancer.

Authors:  Gairin Dancey; Richard H Begent; Tim Meyer
Journal:  Target Oncol       Date:  2009-10-08       Impact factor: 4.493

8.  Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma--implications for radioimmunotherapy.

Authors:  G M Boxer; R H Begent; A M Kelly; P J Southall; S B Blair; N A Theodorou; P M Dawson; J A Ledermann
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

9.  Limits of Tumor Detectability in Nuclear Medicine and PET.

Authors:  Yusuf Emre Erdi
Journal:  Mol Imaging Radionucl Ther       Date:  2012-04-01

10.  Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies.

Authors:  D M Lane; K F Eagle; R H Begent; L D Hope-Stone; A J Green; J L Casey; P A Keep; A M Kelly; J A Ledermann; M G Glaser
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.